Cargando…

Chimeric HCMV/HSV-1 and Δγ(1)34.5 oncolytic herpes simplex virus elicit immune mediated antigliomal effect and antitumor memory()()

Malignant gliomas are the most common primary brain tumor and are characterized by rapid and highly invasive growth. Because of their poor prognosis, new therapeutic strategies are needed. Oncolytic virotherapy (OV) is a promising strategy for treating cancer that incorporates both direct viral repl...

Descripción completa

Detalles Bibliográficos
Autores principales:	Ghonime, Mohammed G., Jackson, Josh, Shah, Amish, Roth, Justin, Li, Mao, Saunders, Ute, Coleman, Jennifer, Gillespie, G. Yancey, Markert, James M., Cassady, Kevin A.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Neoplasia Press 2017
Materias:	Original article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6002352/ https://www.ncbi.nlm.nih.gov/pubmed/29216507 http://dx.doi.org/10.1016/j.tranon.2017.10.005

Ejemplares similares

Preclinical Evaluation of Oncolytic Δγ (1)34.5 Herpes Simplex Virus Expressing Interleukin-12 for Therapy of Breast Cancer Brain Metastases
por: Cody, James J., et al.
Publicado: (2012)

Pre-clinical Assessment of C134, a Chimeric Oncolytic Herpes Simplex Virus, in Mice and Non-human Primates
por: Cassady, Kevin A., et al.
Publicado: (2017)

Pediatric glioma stem cells: biologic strategies for oncolytic HSV virotherapy
por: Friedman, Gregory K., et al.
Publicado: (2013)

Construction of Various γ34.5 Deleted Fluorescent-Expressing Oncolytic herpes Simplex type 1 (oHSV) for Generation and Isolation of HSV-Based Vectors
por: Abdoli, Shahriyar, et al.
Publicado: (2017)

Preclinical Evaluation of Engineered Oncolytic Herpes Simplex Virus for the Treatment of Neuroblastoma
por: Gillory, Lauren A., et al.
Publicado: (2013)

Effect of Repeat Dosing of Engineered Oncolytic Herpes Simplex Virus on Preclinical Models of Rhabdomyosarcoma()
por: Waters, Alicia M., et al.
Publicado: (2016)

Preclinical Evaluation of Engineered Oncolytic Herpes Simplex Virus for the Treatment of Pediatric Solid Tumors
por: Megison, Michael L., et al.
Publicado: (2014)

The Roles of Host and Viral Antibody Fc Receptors in Herpes Simplex Virus (HSV) and Human Cytomegalovirus (HCMV) Infections and Immunity
por: Jenks, Jennifer A., et al.
Publicado: (2019)

γ(1)34.5-Deleted HSV-1 Expressing Human Cytomegalovirus IRS1 Gene Kills Human Glioblastoma Cells as Efficiently as Wild-type HSV-1 in Normoxia or Hypoxia
por: Friedman, Gregory K., et al.
Publicado: (2014)

The Effect of Herpes Simplex Virus-Type-1 (HSV-1) Oncolytic Immunotherapy on the Tumor Microenvironment
por: Uche, Ifeanyi Kingsley, et al.
Publicado: (2021)

Oncolytic Virus-Based Cytokine Expression to Improve Immune Activity in Brain and Solid Tumors
por: Pearl, Taylor M., et al.
Publicado: (2019)

Oncolytic Herpes Simplex Virus Immunotherapy for Brain Tumors: Current Pitfalls and Emerging Strategies to Overcome Therapeutic Resistance
por: Totsch, Stacie K., et al.
Publicado: (2019)

Modulation of the Intratumoral Immune Landscape by Oncolytic Herpes Simplex Virus Virotherapy
por: Yin, Jie, et al.
Publicado: (2017)

Targeting Pediatric Cancer Stem Cells with Oncolytic Virotherapy
por: Friedman, Gregory K., et al.
Publicado: (2012)

Pediatric cancer gone viral. Part I: strategies for utilizing oncolytic herpes simplex virus-1 in children
por: Cripe, Timothy P, et al.
Publicado: (2015)

Oncolytic herpes simplex virus and immunotherapy
por: Ma, Wenqing, et al.
Publicado: (2018)

Eliciting an immune-mediated antitumor response through oncolytic herpes simplex virus-based shared antigen expression in tumors resistant to viroimmunotherapy
por: Ghonime, Mohammed G, et al.
Publicado: (2021)

Efficacy of Systemically Administered Retargeted Oncolytic Herpes Simplex Viruses—Clearance and Biodistribution in Naïve and HSV-Preimmune Mice
por: Vannini, Andrea, et al.
Publicado: (2023)

Pediatric cancer gone viral. Part II: potential clinical application of oncolytic herpes simplex virus-1 in children
por: Friedman, Gregory K, et al.
Publicado: (2015)

The Antiviral Apparatus: STING and Oncolytic Virus Restriction
por: Lee, Joel, et al.
Publicado: (2019)

Retargeting Strategies for Oncolytic Herpes Simplex Viruses
por: Campadelli-Fiume, Gabriella, et al.
Publicado: (2016)

IL-12 Expressing oncolytic herpes simplex virus promotes anti-tumor activity and immunologic control of metastatic ovarian cancer in mice
por: Thomas, Eric D., et al.
Publicado: (2016)

Potent efficacy signals from systemically administered oncolytic herpes simplex virus (HSV1716) in hepatocellular carcinoma xenograft models
por: Braidwood, Lynne, et al.
Publicado: (2014)

STING Restricts oHSV Replication and Spread in Resistant MPNSTs but Is Dispensable for Basal IFN-Stimulated Gene Upregulation
por: Lee, Joel M., et al.
Publicado: (2019)

Histone Deacetylase Inhibitors Improve the Replication of Oncolytic Herpes Simplex Virus in Breast Cancer Cells
por: Cody, James J., et al.
Publicado: (2014)

Pneumomediastinum and Pneumothorax Associated with Herpes Simplex Virus (HSV) Pneumonia
por: López-Rivera, Fermín, et al.
Publicado: (2018)

Oncolytic Herpes Simplex Virus-Based Therapies for Cancer
por: Aldrak, Norah, et al.
Publicado: (2021)

Combination strategies enhance oncolytic virotherapy
por: Friedman, Gregory K., et al.
Publicado: (2017)

HSV-NIS, an oncolytic herpes simplex virus type 1 encoding human sodium iodide symporter for preclinical prostate cancer radiovirotherapy
por: Li, H, et al.
Publicado: (2013)

Newly Characterized Murine Undifferentiated Sarcoma Models Sensitive to Virotherapy with Oncolytic HSV-1 M002
por: Ring, Eric K., et al.
Publicado: (2017)

1410. Neonatal Herpes Simplex Virus (HSV) Infection: Is It the Only Pathogen?
por: Dendi, Alvaro, et al.
Publicado: (2020)

Presage of oncolytic virotherapy for oral cancer with herpes simplex virus
por: Yura, Yoshiaki
Publicado: (2017)

The Current State of Oncolytic Herpes Simplex Virus for Glioblastoma Treatment
por: Nguyen, Hong-My, et al.
Publicado: (2021)

Replication and Spread of Oncolytic Herpes Simplex Virus in Solid Tumors
por: Hong, Bangxing, et al.
Publicado: (2022)

Preclinical Toxicology of rQNestin34.5v.2: An Oncolytic Herpes Virus with Transcriptional Regulation of the ICP34.5 Neurovirulence Gene
por: Chiocca, E. Antonio, et al.
Publicado: (2020)

The Herpes Simplex Virus Neurovirulence Factor γ34.5: Revealing Virus–Host Interactions
por: Wilcox, Douglas R., et al.
Publicado: (2016)

False Positive PCR for Herpes Simplex Virus (HSV) in Childhood CNS Infections
por: Sasan, M S
Publicado: (2012)

Treatment of breast cancer stem cells with oncolytic herpes simplex virus
por: Li, J, et al.
Publicado: (2012)

Herpes Simplex Virus Oncolytic Immunovirotherapy: The Blossoming Branch of Multimodal Therapy
por: Menotti, Laura, et al.
Publicado: (2020)

Oncolytic herpes simplex virus infects myeloma cells in vitro and in vivo
por: Ghose, Jayeeta, et al.
Publicado: (2021)

Cannot write session to /tmp/vufind_sessions/sess_7lso7ilpnibfuv9ng8e5g5o123